Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229722 · ClinicalTrials.gov registry record · NA
ARemind: A Personalized System to Remind for Adherence
A NA study of Medication Adherence, sponsored by Dimagi.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01229722: Completed NA study of Medication Adherence, sponsored by Dimagi.
NCT01229722 is a NA study of Medication Adherence that has completed, run by Dimagi. The registered enrollment target is 70 participants, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01229722, a NA study of Medication Adherence, has completed, sponsored by Dimagi.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The main aim of this phase II proposal is to continue and complete development of a cellular phone-based system that assists patients with their medication adherence. Adherence reports will be developed with feedback from patients and providers. Software for patients to report their four day recall adherence through text messaging or short message service (SMS) or interactive voice response (IVR) will be built. An initial qualitative study will evaluate the adherence reports, 4-day adherence recalls, and inform the development of content for reminder text messages that could be resistant to user fatigue. A redesigned system will be tested through a 3-week longitudinal study of 15 patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). An intervention module will have an analytics engine to track adherence levels and personalize delivery of reminder messages. A clinic appointment module will perform patient appointment reminders. The final system with these modules will be tested through a 24-week efficacy study. A total of 115 patients and providers will be involved in the three user studies.
Primary Outcome
MEMS pill caps or boxes will be used to monitor adherence. Each participant will place the drug containing the protease inhibitor, or, if no such drug is being taken, the drug with the highest dosing frequency, inside of a MEMS device, which automatically records each time the pillbox was opened. Participants will bring this to the clinic during their regularly scheduled visits, and those daily measurements will be downloaded to a clinic machine.
Conditions Studied
Interventions
- DEVICE Beeper
- DEVICE ARemind
Study Locations (1)
Massachusetts
- Center for HIV/AIDS Care and Research, Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-01 |
| Phase | NA |
What the finished NCT01229722 record still lists
NCT01229722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Medication Adherence appearing as the primary indexed condition, and to 2 interventions - of which Beeper is the first listed.
NCT01229722 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01229722 about?
NCT01229722 is a clinical study titled "ARemind: A Personalized System to Remind for Adherence". The main aim of this phase II proposal is to continue and complete development of a cellular phone-based system that assists patients with their medication adherence. Adherence reports will be developed with feedback from patients and providers. Software for patients to report their four day recall ...
What is the current status of trial NCT01229722?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2011-10. Estimated completion is 2013-01.
What conditions does trial NCT01229722 study?
This clinical trial studies the following conditions: Medication Adherence.
What interventions are being tested in trial NCT01229722?
The interventions under investigation include: Beeper (DEVICE), ARemind (DEVICE).
Who is sponsoring clinical trial NCT01229722?
This trial is sponsored by Dimagi, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01229722 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Adherence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01229722's enrollment target sits among peer trials
70 40th of 52 higher than 11 of 52 other Medication Adherence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Medication Adherence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Medication Adherence Program
RECRUITING · NA
-
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
RECRUITING · NA
-
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
RECRUITING · NA
-
Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia